2B70C69F-DE54-4C78-B326-5CCEE15916FB
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 35.41392904073587
- age_years
- 45
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.503
- CHOLESTEROL_HOMEOSTASIS+0.420
- ANDROGEN_RESPONSE+0.396
- MITOTIC_SPINDLE+0.388
- PROTEIN_SECRETION+0.385
- WNT_BETA_CATENIN_SIGNALING+0.356
- HEDGEHOG_SIGNALING+0.322
- UV_RESPONSE_DN+0.319
- UNFOLDED_PROTEIN_RESPONSE+0.304
- MTORC1_SIGNALING+0.290
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.420
- ANGIOGENESIS-0.287
- INTERFERON_GAMMA_RESPONSE-0.287
- COAGULATION-0.264
- IL6_JAK_STAT3_SIGNALING-0.260
- INTERFERON_ALPHA_RESPONSE-0.224
- COMPLEMENT-0.215
- KRAS_SIGNALING_DN-0.191
- INFLAMMATORY_RESPONSE-0.158
- SPERMATOGENESIS-0.158
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C138638F-C6CB-439B-BFF0-CF097E0B421E | — | — | 0.884 |
| 2 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.882 |
| 3 | 92A04345-2DCA-49F5-801F-926B59255925 | — | — | 0.881 |
| 4 | 9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C | — | — | 0.880 |
| 5 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.864 |
| 6 | DE716AF0-930E-4747-B7FE-4AFAA45212DC | — | — | 0.853 |
| 7 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.851 |
| 8 | 37A8E941-F86F-449A-86E4-833AC349111F | — | — | 0.848 |
| 9 | SRR934986 | — | — | 0.842 |
| 10 | 61C38CFD-F57F-48D2-9FC7-81776647CF0E | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.503 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.396 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.388 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.385 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.356 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.322 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.319 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.304 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.257 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.231 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.219 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.193 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.159 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.145 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |